- Global Pharma News & Resources

Research Article Cites Cleanascite™ To Study Lipid Metabolism in Cancer

MONMOUTH JUNCTION, NJ, August 6, 2019 -- Biotech Support Group reports on a recent research article describing the simplicity and efficiency of their lipid clearance sample preparation technology for studying cell response associated with peritoneal metastases in ovarian cancer cells. The citation is:

Chen, Rain R., et al. "Targeting of lipid metabolism with a metabolic inhibitor cocktail eradicates peritoneal metastases in ovarian cancer cells." Communications Biology 2 (2019).

Ovarian cancer is an intra-abdominal tumor in which the presence of ascites facilitates metastatic dissemination, and is associated with poor prognosis. However, the significance of metabolic alterations in ovarian cancer cells in the ascites microenvironment remains unclear. In this study, the authors investigated whether reprogramming of lipid metabolism in ovarian cancer cells could modulate cell viability and aggressiveness. The article states: ”To determine whether fatty acids in OCM are the primary energy source, fatty acids from OCM was first removed by Cleanascite™ Lipid Removal Reagent... Then, XTT cell proliferation assays showed that the growth rate of ovarian cancer cells was remarkably reduced in cells cultured in Cleanascite-treated OCM. Likewise, co-treatment with Cleanascite and OCM significantly attenuated the increased cell migration and invasion capacities of ES-2 and SKOV3 cells. These findings suggest that the fatty acid-enriched OCM provides as an energy source for supporting tumor growth and aggressiveness of ovarian cancer cells.”. The authors conclude that targeting the lipid metabolism signaling axis impedes ovarian cancer peritoneal metastases. 

 “I am pleased that using Cleanascite™ helped to identify fatty acids as a mediator of cancer cell response. This demonstrates the advantage of using an aqueous suspension product with no harmful solvents, so one can challenge cells for responsiveness. This ultimately helps researchers decide whether a lipid factor is or is not consistent with cancer growth and metastatic potential. We highlight many such cell response references in our recently published whitepaper.” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

To download whitepaper entitled “Cleanascite™ -  Lipid Removal and Cell Response Applications”, visit: ResponseReferenceApplications121218.pdf

For more information visit: Cleanascite™ Lipid Removal Reagent and Clarification, at  .htm

About Biotech Support Group LLC Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NuGel™ for functional proteomics. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to         

Editor Details

  • Company:
    • Biotech Support Group LLC
  • Name:
    • Matthew Kuruc
Last Updated: 12-Aug-2019